Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR‐mutated non‐small‐cell lung cancer: A case report
Abstract A therapeutic option for advanced non‐small‐cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) resistance is a clinical challenge. The clinical outcomes of pembrolizumab in those patients is inconclusive. Cytokine release syndrome...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-05-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14390 |